Ftse Mib
33.818,91
0,21%
DAX
17.959,14
0,21%
S&P 500
5.018,39
-0,34%
NASDAQ Composite
15.605,48
-0,33%
Bitcoin
58.271,10
0,06%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ ENDRA Life Sciences Inc (NDRA) ENDRA Life Sciences Inc (NDRA) Notizie

ENDRA Life Sciences Inc

NDRA
0,2875
0,00 (0,00%)
Pre Mercato
Ultimo aggiornamento: 13:03:49
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
28/3/202421:05BWENDRA Life Sciences Reports Fourth Quarter and Full Year..
21/3/202413:00BWENDRA Life Sciences to Report Fourth Quarter 2023 Financial..
27/2/202414:00BWENDRA Life Sciences Installs First TAEUS System in the UK
23/2/202423:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/2/202414:00BWNew ICD-10-CM Code by the World Health Organization Paves..
14/2/202414:30BWENDRA Life Sciences Bolsters TAEUS® System Intellectual..
29/12/202323:07EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
29/11/202314:00BWENDRA Life Sciences Secures 39th U.S. Patent for TAEUS®..
27/11/202314:00BWENDRA Life Sciences to Participate in The Benchmark..
14/11/202322:05BWENDRA Life Sciences Reports Third Quarter 2023 Financial..
14/11/202322:02EDGAR2Form 8-K - Current report
08/11/202314:00BWENDRA Life Sciences Achieves Intellectual Property Milestone..
07/11/202322:05BWENDRA Life Sciences to Report Third Quarter 2023 Financial..
06/11/202314:00BWENDRA to Host Multidisciplinary Clinical Discussion on..
07/9/202314:00BWAbstract for ENDRA Life Sciences' TAEUS System Accepted for..
30/8/202314:00BWENDRA Life Sciences' TAEUS De Novo Submission Advances to..
23/8/202314:00BWENDRA Life Sciences Expands Intellectual Property with..
14/8/202322:45EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
14/8/202322:13EDGAR2Form 8-K - Current report
14/8/202322:05BWENDRA Life Sciences Reports Second Quarter 2023 Financial..
14/8/202319:30BWENDRA Life Sciences Submits De Novo Request for its TAEUS®..
10/8/202314:01EDGAR2Form 8-K - Current report
01/8/202314:00BWENDRA Life Sciences to Report Second Quarter 2023 Financial..
25/7/202322:02EDGAR2Form 8-K - Current report
06/7/202323:25EDGAR2Form 8-K - Current report
06/7/202323:25EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
06/7/202322:45BWENDRA Life Sciences Announces Adjournment of 2023 Annual..
07/6/202314:00BWStudy Highlighting ENDRA Life Sciences’ TAEUS Technology to..
15/5/202322:05BWENDRA Life Sciences Reports First Quarter 2023 Financial..
04/5/202314:00BWENDRA Life Sciences to Report First Quarter 2023 Financial..
Apertura: Min: Max:
Chiusura: 0,2875

La tua Cronologia

NASDAQ
NDRA
ENDRA Life Sciences
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network